WALTHAM, Mass. — Thermo Fisher Scientific Inc. said it remains positioned for long-term growth as the company highlighted its market position, capital strategy and financial outlook during its 2026 Investor Day.
The Waltham-based life sciences and diagnostics company said Chairman and CEO Marc N. Casper and other senior executives outlined Thermo Fisher’s role in serving researchers, drug developers and other customers across global scientific markets.
“Our customers value Thermo Fisher as their trusted partner,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. “Our unique scale and depth of capabilities advance scientific discovery and position us incredibly well in an increasingly AI-enabled world.”
Casper said the company’s growth strategy, operational discipline and approach to capital deployment have helped Thermo Fisher gain market share and create long-term value.
“We have a track record of delivering share gain through our proven growth strategy, operational excellence through our PPI Business System and creating value through disciplined capital deployment. We are incredibly well positioned in attractive and improving end markets to create value for our stakeholders and build a very bright future for our company. We are actively managing the company to deliver outstanding financial performance in the short- and long-term,” Casper said.
Thermo Fisher said it serves a $255 billion market supported by improving demand trends and long-term growth drivers. The company said its industry-leading businesses benefit from the scale and breadth of its combined capabilities, which it said help customers advance scientific discovery and improve productivity.
The company pointed to innovation, its role as a trusted partner and its commercial reach as key drivers of market-share gains. Thermo Fisher said its technologies help customers accelerate innovation, while its expertise and global scale allow it to address complex scientific and operational challenges.
Thermo Fisher also emphasized its Practical Process Improvement Business System, known as PPI, which the company said supports continuous improvement across quality, productivity and customer service.
The company said artificial intelligence is expected to be a significant accelerator for its future growth. Thermo Fisher said AI could help speed scientific breakthroughs, improve productivity in drug discovery and generate additional investment in customer drug pipelines. The company said it is positioned to benefit from AI-driven growth because of its presence across the drug development value chain.
Thermo Fisher also said AI and automation are helping expand the impact of PPI across the company.
The company said its capital strategy will continue to combine strategic acquisitions with returns of capital to shareholders. Thermo Fisher said that approach is intended to strengthen its industry leadership and create shareholder value.
Thermo Fisher said its long-term outlook calls for 7% organic revenue compound annual growth and low-teens adjusted earnings-per-share growth.
